TD-2749

DB05905ExperimentalSmall molecule

TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such...

Primary indication: Investigated for use/treatment in constipation, gastrointestinal diseases and disorders (miscellaneous), gastroparesis, and irritable bowel syndrome (IBS).Curator reviewed
Formula / weight: C₂₆H₃₈N₆O₂ · 466.63 g/mol (avg)
Code names: TD-2749

Resolves to

Compound

UNII0ZN0AQ6SBVCAS863248-59-3ChEMBLCHEMBL2059590

Structure

InChIKeyZQMXTDPQEHZTBG-KOUNCHBCSA-NSMILESCC(C)N1N=C(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3CCN2CCN(CC2)C(C)=O)C2=CC=CC=C12

Targets

Q13639HTR4

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with TD-2749, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account